ATE219791T1 - Antikörper gegen den urokinaserezeptor und ihre verwendung - Google Patents

Antikörper gegen den urokinaserezeptor und ihre verwendung

Info

Publication number
ATE219791T1
ATE219791T1 AT91918632T AT91918632T ATE219791T1 AT E219791 T1 ATE219791 T1 AT E219791T1 AT 91918632 T AT91918632 T AT 91918632T AT 91918632 T AT91918632 T AT 91918632T AT E219791 T1 ATE219791 T1 AT E219791T1
Authority
AT
Austria
Prior art keywords
par
mammal
antibodies
inhibiting
preventing
Prior art date
Application number
AT91918632T
Other languages
English (en)
Inventor
Keld Dan
Ebbe Ronne
Niels Behrendt
Vincent Ellis
Gunilla Hoyer-Hansen
Charles Pyke
Nils Bruenner
Original Assignee
Cancerforskningsfonden Af 1989
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancerforskningsfonden Af 1989 filed Critical Cancerforskningsfonden Af 1989
Application granted granted Critical
Publication of ATE219791T1 publication Critical patent/ATE219791T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/972—Plasminogen activators
    • G01N2333/9723—Urokinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
AT91918632T 1990-10-18 1991-10-18 Antikörper gegen den urokinaserezeptor und ihre verwendung ATE219791T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPCTDK9000270 1990-10-18
PCT/DK1991/000319 WO1992007083A1 (en) 1990-10-18 1991-10-18 Antibodies against the urokinase receptor and their use

Publications (1)

Publication Number Publication Date
ATE219791T1 true ATE219791T1 (de) 2002-07-15

Family

ID=8153643

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91918632T ATE219791T1 (de) 1990-10-18 1991-10-18 Antikörper gegen den urokinaserezeptor und ihre verwendung

Country Status (8)

Country Link
EP (2) EP0574391B1 (de)
JP (1) JPH07500486A (de)
AT (1) ATE219791T1 (de)
AU (1) AU661978B2 (de)
CA (1) CA2094276C (de)
DE (1) DE69133049T2 (de)
ES (1) ES2179036T3 (de)
WO (1) WO1992007083A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2162855A1 (en) * 1993-06-01 1994-12-08 Steven Rosenberg Expression of urokinase plasminogen activator inhibitors
US6248715B1 (en) 1993-06-01 2001-06-19 Chiron Corporation Method of treating a urokinase-type plasminogen activator-mediated disorder
JP2852192B2 (ja) 1994-07-08 1999-01-27 カンセアフォースクニングスフォンデン・アフ・１９８９（フォンデン・チル・フレメ・アフ・エクスペリメンテル・カンセアフォースクニング） ｕＰＡＲのドメイン２＋３のｕＰＡ結合部位および抗体
US6077508A (en) * 1998-03-23 2000-06-20 American Diagnostica Inc. Urokinase plasminogen activator receptor as a target for diagnosis of metastases
DE50015293D1 (de) * 1999-04-13 2008-09-11 Wilex Ag Diagnostischer und therapeutischer Einsatz von Antikörpern gegen den Urokinase-Rezeptor
US20030096733A1 (en) * 2001-07-10 2003-05-22 Omnio Ab Novel drug targets for arthritis
US20040241690A1 (en) * 2001-08-03 2004-12-02 Takayuki Souka Method of evaluating biocompatibility
JP2004137151A (ja) * 2002-10-15 2004-05-13 Keio Gijuku 脳腫瘍の治療・診断薬
TW200813091A (en) * 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
JPWO2008038813A1 (ja) * 2006-09-28 2010-01-28 株式会社島津製作所 パラフィン包埋標本の脱パラフィン法及びパラフィン包埋標本の解析法
DK2117571T3 (en) 2006-12-08 2017-05-08 Monopar Therapeutics Inc Urokinase-type plasminogen activator receptor epitope
US20120093936A1 (en) * 2009-04-07 2012-04-19 Velin-Pharma A/S Method and device for treatment of conditions associated with inflammation or undesirable activation of the immune system
US10126216B2 (en) 2011-02-17 2018-11-13 Ventana Medical Systems, Inc. Method for tissue sample fixation
US10539487B2 (en) 2010-03-04 2020-01-21 Ventana Medical Systems, Inc. Systems and methods for monitoring tissue sample processing
EP2542883B1 (de) 2010-03-04 2019-10-02 Ventana Medical Systems, Inc. Verarbeitungssystem zur verarbeitung von proben mit schallenergie
MA41842A (fr) 2015-03-31 2018-02-06 Oblique Therapeutics Ab Nouveaux procédés de sélection d'épitope
GB201617002D0 (en) 2016-10-06 2016-11-23 Oblique Therapeutics Ab Multi-protease method

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923807A (en) * 1984-05-18 1990-05-08 New England Medical Center Hospitals Inc. Arg-Serpin human plasminogen activator inhibitor designated PAI-2
DE3902021A1 (de) * 1989-01-20 1990-07-26 Entec Verwendung von antipeptidergen mitteln, gegebenenfalls in kombination mit anti-androgenen mitteln zur behandlung des humanen prostatakarzinoms
WO1990012091A1 (en) * 1989-04-07 1990-10-18 Cancerforskningsfondet Af 1989 Urokinase-type plasminogen activator receptor

Also Published As

Publication number Publication date
EP1281404A2 (de) 2003-02-05
CA2094276C (en) 2005-08-23
AU661978B2 (en) 1995-08-17
EP0574391A1 (de) 1993-12-22
DE69133049T2 (de) 2003-01-02
CA2094276A1 (en) 1992-04-19
AU8757291A (en) 1992-05-20
JPH07500486A (ja) 1995-01-19
DE69133049D1 (de) 2002-08-01
WO1992007083A1 (en) 1992-04-30
ES2179036T3 (es) 2003-01-16
EP1281404A3 (de) 2004-04-07
EP0574391B1 (de) 2002-06-26

Similar Documents

Publication Publication Date Title
DE69133049D1 (de) Antikörper gegen den urokinaserezeptor und ihre verwendung
NO922238D0 (no) Aktiverbare, fibrinolytiske og antitrombotiske proteiner
KR910018039A (ko) 양특이성 단일클론 항체, 이들의 생산 및 이용
DE69033653D1 (de) Plasminogen-aktivator-rezeptor vom urokinasetyp
DE69229911D1 (de) Monoklonale antikörper gegen rezeptor-induzierte bindungsstellen
DK0724456T3 (da) CD40-Antistoffer
ATE72726T1 (de) Verwendung eins pflanzensubstrates.
DE10199051I2 (de) Modifizierte Antik¦rper.
ATE421976T1 (de) Fab fragmentbibliotheken und verfahren für deren verwendung
DE69432645D1 (de) Monoklonale antikörper gegen isozyme der thymidinkinase
NO902833D0 (no) Oksidativ denaturering av proteinanalytter.
ATE148891T1 (de) Hexapeptide als liganden des anaphylatoxin- rezeptors
ATE99674T1 (de) Substituierte arylharnstoffe als stark wirksame suessstoffe.
NO172596C (no) Apolipoprotein b-spesifikke monoklonale antistoffer produsert av to nye hybridomer, anvendelse av disse og diagnostiske systemer inneholdende disse
SE8301794D0 (sv) Plasminogenaktivatorkomplex
DE68915112D1 (de) Spiro-isochinolin-pyrrolidin-tetrone und Analoge davon, verwendbar als Aldosereduktase-Inhibitoren.
DE69025561D1 (de) Speicherzelle mit schwebendem Gatter und ihre Anwendung für einen Halbleiterspeicher
NO173901C (no) Fremgangsmaate, monoklonalt antistoff og sett for maaling av vevplasminogenaktivator-aktivitet
ES2053704T3 (es) Un metodo de estabilizacion de una composicion acuosa consistente en uno o mas anticuerpos monoclonales.
DK0672685T3 (da) Monoklonalt antistof specifik for tumor cytotoxisk faktor (TCF-11)
FR2415565A1 (fr) Perfectionnement a un wagon
ATE56617T1 (de) Anti-urokinase monoklonaler antikoerper, seine herstellung und verwendung.
DE59003265D1 (de) Verwendung von nor-verapamil und nor-gallopamil als antiarteriosklerotica.
DE69133082D1 (de) Gegen aus Thrombin und Thrombininhibitoren gebildete Komplexe gerichtete monoklonale Antikörper
GR3023701T3 (en) Process for selective removal of salivary alpha-amylase and assay for pancreatic alpha-amylase